ES2138595T3 - Inhibidores de citoquinas. - Google Patents

Inhibidores de citoquinas.

Info

Publication number
ES2138595T3
ES2138595T3 ES92907362T ES92907362T ES2138595T3 ES 2138595 T3 ES2138595 T3 ES 2138595T3 ES 92907362 T ES92907362 T ES 92907362T ES 92907362 T ES92907362 T ES 92907362T ES 2138595 T3 ES2138595 T3 ES 2138595T3
Authority
ES
Spain
Prior art keywords
production
inhibiting
mammal
cytokin
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907362T
Other languages
English (en)
Inventor
Alison Mary Badger
Wanda Bernadette High
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of ES2138595T3 publication Critical patent/ES2138595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DISPONE DE METODOS DE INHIBIR LA PRODUCCION DE CITOQUINAS, PARTICULARMENTE INHIBIENDO LA PRODUCCION DE INTERLEUKIN 1 E INHIBIENDO LA PRODUCCION DEL FACTOR DE NECROSIS TUMORAL EN UN MAMIFERO QUE TENGA NECESIDAD DE ELLO, Y QUE COMPRENDE LA ADMINISTRACION A TAL MAMIFERO DE UNA CANTIDAD EFICAZ DE UN DERIVADO DE AZASPIRANA.
ES92907362T 1991-02-19 1992-02-18 Inhibidores de citoquinas. Expired - Lifetime ES2138595T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65757891A 1991-02-19 1991-02-19

Publications (1)

Publication Number Publication Date
ES2138595T3 true ES2138595T3 (es) 2000-01-16

Family

ID=24637788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907362T Expired - Lifetime ES2138595T3 (es) 1991-02-19 1992-02-18 Inhibidores de citoquinas.

Country Status (14)

Country Link
US (2) US5602166A (es)
EP (1) EP0572537B1 (es)
JP (1) JP3162071B2 (es)
KR (1) KR930702975A (es)
AT (1) ATE186641T1 (es)
AU (1) AU657745B2 (es)
CA (1) CA2104214C (es)
DE (1) DE69230314T2 (es)
DK (1) DK0572537T3 (es)
ES (1) ES2138595T3 (es)
GR (1) GR3032612T3 (es)
IE (1) IE920508A1 (es)
WO (1) WO1992014462A1 (es)
ZA (1) ZA921120B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201804D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9201803D0 (en) * 1992-01-28 1992-03-11 Smithkline Beecham Corp Methods
GB9315351D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315306D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
GB9315340D0 (en) * 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9414902D0 (en) * 1994-07-23 1994-09-14 Smithkline Beecham Corp Methods
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
EP0837678A1 (en) * 1995-07-13 1998-04-29 Smithkline Beecham Corporation N,n-dimethyl-8,8-dipropyl-2-azaspiro 4,5]decane-2-propanamine dimaleate
BR9709007A (pt) * 1996-05-17 2000-01-04 Anormed Inc Uso de azaspirano substituìdo no tratamento da asma.
GB2309167A (en) * 1997-05-10 1997-07-23 Anormed Inc The use of azaspiranes in the treatment of Alzheimer's disease
CO5190696A1 (es) * 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
WO2002080970A1 (en) * 2001-03-23 2002-10-17 Regents Of The University Of California Method for inhibiting articular cartilage matrix calcification
US7674838B2 (en) * 2002-04-05 2010-03-09 Henkel Corporation Curable foam elastomeric compositions
MXPA05009708A (es) * 2003-03-10 2006-05-25 Callisto Pharmaceuticals Inc Metodo para el tratamiento de cancer con composiciones de azaspirina.
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106552A (en) 1960-07-19 1963-10-08 Geschickter Fund Med Res Nu-substituted azaspiranes and azaspirane-diones and processes for their preparation
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
WO1989011540A1 (en) 1988-05-27 1989-11-30 Synergen, Inc. Interleukin-1 inhibitors

Also Published As

Publication number Publication date
IE920508A1 (en) 1992-08-26
WO1992014462A1 (en) 1992-09-03
DE69230314D1 (de) 1999-12-23
EP0572537A4 (en) 1993-10-14
KR930702975A (ko) 1993-11-29
CA2104214C (en) 2004-04-27
EP0572537B1 (en) 1999-11-17
CA2104214A1 (en) 1992-08-20
DK0572537T3 (da) 2000-03-27
US5900430A (en) 1999-05-04
JPH06505483A (ja) 1994-06-23
JP3162071B2 (ja) 2001-04-25
DE69230314T2 (de) 2000-02-24
GR3032612T3 (en) 2000-05-31
US5602166A (en) 1997-02-11
EP0572537A1 (en) 1993-12-08
ATE186641T1 (de) 1999-12-15
ZA921120B (en) 1993-01-27
AU657745B2 (en) 1995-03-23
AU1463392A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
DK0572537T3 (da) Cytokinnhibitorer
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
ATE329622T1 (de) Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
BG98902A (bg) Имидазолови производни и тяхната употреба като инхибитори на цитокин
FI981437L (fi) PDE III, PDE IV ja TNF inhibiittoreina käyttökelpoisia imidejä
FI896193A0 (fi) Biosidiset koostumukset
CY1107545T1 (el) Μεθοδοι για την προκληση θανατου καρκινικων κυτταρων και υποχωρησης του ογκου
NO983189L (no) Nye substituerte imidazolforbindelser
DK0527879T3 (da) Synergistiske terapeutiske præparater og fremgangsmåder.
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
ES2049690T1 (es) Derivados de taxano, su preparacion y uso en oncologia.
NO905090L (no) Interleukin-1-inhibitorer og fremgangsmaate til deres fremstilling.
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
NO925041D0 (no) Nye 2-sakkarinylmetylaryl- og aryloksyacetater som er nyttige som proteolytiske enzymerinhibitorer
NO890046L (no) Disubstituerte pyridiner.
DE69535961D1 (de) T-zellaktivierung
ITTO910787A0 (it) Amplificatore di potenza, in particolare di tipo audio
BG100248A (bg) Инхибитори на скваленсинтетаза
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
DE69217221D1 (de) Hydrochinonderivate und diese enthaltende Antioxydantien sowie Tumorinhibitoren
MX9206135A (es) Metodos
FI914776A7 (fi) Inhibiittoreita kasvainkuoliotekijän muodostumiselle, menetelmä niidenvalmistamiseksi ja niiden käyttö
MX9202713A (es) Azapiranos inmunomoduladores.
MX9602407A (es) Composiciones farmaceuticas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 572537

Country of ref document: ES